CSL Limited (ASX: CSL)
Health Care · Biotechnology · AU
AU$173.64
+2.68% today · -19.8% 1Y
CSL Limited (ASX: CSL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $59.49B and employs 29,000 people.
Over the last twelve months the share price has lost 19.8%, trading between 90.00 and 228.30.
Tweenvest scores CSL Limited across four factors: quality 83/100, value 78/100, growth 49/100, dividend 68/100. Its strongest factor is quality.
CSL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $59.49B
- Revenue (TTM)
- $15.80B
- P/E
- —
- EPS
- -5.35
- Dividend yield
- 2.41%
- Beta (5Y)
- 0.09
- 52-week high
- AU$228.30
- 52-week low
- AU$90.00
- Avg volume (3M)
- —
- Shares outstanding
- 478.91M
- Employees
- 29,000
- Next earnings
- —
About CSL Limited
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
- ISIN
- AU000000CSL8
- Founded
- 1916
- Listed since
- Jun 1, 1994
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| Natera, Inc.NasdaqGS: NTRA | $48.53B | $336.71 | +2.74% |
Figures last refreshed Aug 18, 2026.